Description: uniQure BV, a biopharmaceutical company, develops gene therapies through its modular technology platform for the treatment of genetic or acquired diseases. The company offers Glybera for the treatment of patients with lipoprotein lipase deficiency, an orphan metabolic disease. It also develops a pipeline of additional adeno-associated virus (AAV) based gene therapies, including AMT-060, a gene therapy for the treatment of hemophilia B; AMT-021 for acute intermittent porphyria; AMT-110 for Sanfilippo B syndrome; and AAV2/glial cell line-derived neurotrophic factor for Parkinson's disease, as well as various programs that are in early preclinical development stage. The company has collaborations with Chiesi Farmaceutici S.p.A., Digna Biotech, Institut Pasteur, and University of California San Francisco. uniQure BV was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Home Page: www.uniqure.com
QURE Technical Analysis
Paasheuvelweg 25a
Amsterdam,
1105 BP
Netherlands
Phone:
31 20 240 6000
Officers
| Name | Title |
|---|---|
| Mr. Matthew Craig Kapusta | CEO & Exec. Director |
| Mr. Christian Klemt | CFO, Principal Financial Officer & GM of Amsterdam Site |
| Mr. Pierre Caloz | Chief Operating Officer |
| Dr. Alexander E. Kuta Ph.D. | Exec. VP of Quality & Regulatory Affairs |
| Dr. Ricardo Dolmetsch Ph.D. | Pres of R&D |
| Prof. Hugo Katus | Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany |
| Mr. David Cerveny | Chief Legal Officer, Gen. Counsel & Sec. |
| Dr. Tamara Tugal Ph.D., MBA | Bus. Devel. Director |
| Ms. Erin Boyer | Chief People & Culture Office |
| Ms. Maria E. Cantor | Chief Corp. Affairs Officer |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 27.933 |
|---|---|
| Trailing PE: | 2.8276 |
| Price-to-Book MRQ: | 2.6144 |
| Price-to-Sales TTM: | 17.5893 |
| IPO Date: | 2007-06-20 |
| Fiscal Year End: | December |
| Full Time Employees: | 463 |